Press release March 20th 2018
Bio-Works has opened a sales office in Philadelpia, USA to meet the large demand for separation and purification products for the production of biological medicine in the American market. To be able to support the customers at the right competence level the office will initially be manned with Swedish personnel. Bio-Works will during this year start to build a network of local sales people who will in the future manage the customer relations in USA and Canada.
Mats Johnson, Bio-Works CEO:
”While South Korea is the single most important market for biosimilars, not the least in Asia, USA is the single most important market for agarose based purification of biomolecules for production of original biopharmaceuticals. Many of the original biopharmaceuticals are developed in the US and the rest of the world often copies how the production is done there. Thus it is strategically important to have a good position in the American market. With the establishment of our American office, in combination with our on-going sales activites together with Amicogen in South Korea, we have a good coverage of prioritized markets.”
For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: email@example.com, telephone: +46 70 516 53 37.
Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose based high performance products are used for purificationin the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.